Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker. This channel is responsible for the cardiac pacemaker current (I f ), which regulates heart rate.
The FDA approval of Ivabradine was based on SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine), a randomized, double-blind trial comparing Ivabradine and placebo in 6,558 adults with stable NYHA class II to IV heart failure, left ventricular ejection fraction ≤ 35%, and resting heart rate ≥ 70 bpm This article gives a brief information on this molecule. Indication & Dosage Oral Chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm Adult: In patients with contraindication to or unable to tolerate beta-blockers; or combined with beta-blockers in patients who are inadequately controlled with optimal dose of beta-blockers and whose heart…
